Drug intelligence / Profile preview

cephalexin + levofloxacin

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Combination of cephalexin, a first-generation cephalosporin antibiotic, and levofloxacin, a fluoroquinolone antibiotic. This combination provides broad-spectrum coverage against both gram-positive and gram-negative bacteria. Beta-lactam (cephalexin) and fluoroquinolone (levofloxacin) combinations have shown synergistic effects in treating certain bacterial infections, with studies indicating reduced mortality in less severely ill patients with bacteremia caused by gram-negative bacilli and shorter time to defervescence compared to monotherapy.

Targets

Topo IV (Bacterial Topoisomerase IV)PBP (Penicillin-binding protein family)DNA gyrase

Beyond the preview

Go deeper on cephalexin + levofloxacin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cephalexin + levofloxacin.

Explore the full profile